Advertisement

Topics

GTC Biotherapeutics Company Profile

13:51 EST 17th December 2018 | BioPortfolio

GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins using transgenic animal technology. ATryn®, recombinant human antithrombin, is the first transgenically produced therapeutic protein approved anywhere in the world, having recently been approved by the European Commission (EMEA) for the prophylactic treatment of deep vein thrombosis in patients with hereditary antithrombin deficiency. ATryn® was approved for hereditary antithrombin deficiency in the United States (FDA) in February 2009, and remains the only recombinant form of the molecule available for clinical use. ATryn® is produced in the milk of goats using micro-injection technology to incorporate a human antithrombin transgene. In addition to ATryn®, GTC is developing additional recombinant proteins and monoclonal antibodies. These products have potential applications in hematology, oncology, and autoimmune diseases. GTC has active development and commercialization relationships with Lundbeck Inc. and LFB Paris.

Location

175 Crossing Blvd.
Framingham
Massachusetts
01702
United States of America

Contact

Phone: (508) 620-9700
Fax: (508) 370-3797


News Articles [231 Associated News Articles listed on BioPortfolio]

Asterias Biotherapeutics to merge with BioTime

US-based biotechnology firms BioTime and Asterias Biotherapeutics have entered into a definitive merger agreement to form an integrated company focussed...Read More... The post Asterias Biotherapeutic...

Codexis Appoints Biotherapeutics R&D VP

Dr. Alaoui will be responsible for the biotherapeutics discovery pipeline and acceleration of drug candidates to the clinic

Cancer Research UK launches new research hub for biotherapeutics

Cancer Research UK has launched a global centre of excellence in London to facilitate research on biotherapeutics as a treatment...Read More... The post Cancer Research UK launches new research hub fo...

Pall and Celltheon form strategic biotherapeutics partnership

This partnership will deliver integrated manufacturing solutions for customers developing biotherapeutics

Improving understanding of biotherapeutics and biosimilars

Additional information on biosimilars and biotherapeutics have been published in Europe.

Gene Biotherapeutics sells Excellagen technology platform to Olaregen

Olaregen is a special purpose entity which was formed by an unaffiliated investment group to acquire and commercialize advanced wound healing therapeutics for multiple vertical markets. Gene Biotherap...

BioTime signs merger deal with Asterias Biotherapeutics

The merger of BioTime and Asterias Biotherapeutics will enable to create a major cell therapy company. As per terms of the deal, Asterias stockholders will secure 0.71 common The post BioTime signs m...

SAB Biotherapeutics closes $10mm Series A-2 round

Infectious disease-focused SAB Biotherapeutics Inc. received $10mm in its Series A-2 financing from T. Denny Sanford, who joins SAB's board.

Drugs and Medications [14 Associated Drugs and Medications listed on BioPortfolio]

Plasmanate [TALECRIS BIOTHERAPEUTICS, INC.]

Plasma Protein Fraction (Human) 5%, USPPlasmanate®

Gamastan s/d [TALECRIS BIOTHERAPEUTICS, INC.]

Immune Globulin (Human)GamaSTAN™ S/DSolvent/Detergent Treated

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 5%, USPPlasbumin ®-5

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 5%, USPPlasbumin ®-5

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 20%, USPPlasbumin®-20

PubMed Articles [24 Associated PubMed Articles listed on BioPortfolio]

Synthetic Biology and Engineered Live Biotherapeutics: Toward Increasing System Complexity.

Recent advances in synthetic biology and biological system engineering have allowed the design and construction of engineered live biotherapeutics targeting a range of human clinical applications. In ...

Cell Penetration Profiling Using the Chloroalkane Penetration Assay.

Biotherapeutics are a promising class of molecules in drug discovery, but they are often limited to extracellular targets due to their poor cell penetration. High-throughput cell penetration assays ar...

Live bacterial biotherapeutics in the clinic.

Data-independent oxonium ion profiling of multi-glycosylated biotherapeutics.

The characterization of glycosylation is required for many protein therapeutics. The emergence of antibody and antibody-like molecules with multiple glycan attachment sites has rendered glycan analysi...

Recent advancements, challenges, and practical considerations in the mass spectrometry-based analytics of protein biotherapeutics: A viewpoint from the biosimilar industry.

The extensive analytical characterization of protein biotherapeutics, especially of biosimilars, is a critical part of the product development and registration. High-resolution mass spectrometry becam...

Clinical Trials [4 Associated Clinical Trials listed on BioPortfolio]

Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

The purpose of this study is to: - evaluate the safety profile of a single intravenous administration of AIGIV (containing either 3.5 mg/kg, 7.0 mg/kg or 14.0 mg/kg anti-PA IgG) a...

A Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Mitochondrial Disease Previously Treated in the Stealth BioTherapeutics SPIMM-201 Study

This is a Phase 2, randomized, double-blind, placebo-controlled crossover study which will enroll up to 36 subjects (anticipated) with genetically confirmed mitochondrial disease who have ...

The Effect of OASIS Ultra on Critical Sized Wound Healing

The aim of this study is to evaluate the speed and quality with which OASIS® Ultra (Healthpoint Biotherapeutics; Fort Worth, Texas) increases wound healing in the critical sized defect. ...

Personalized Immunotherapeutics for Antibiotic-resistant Infection

M. A. suffers from hypogammaglobulinemia that has been complicated by refractory Mycoplasma hominis septic arthritis. He has been receiving the antibiotic valnemulin under Emergency Invest...

Companies [106 Associated Companies listed on BioPortfolio]

Axial Biotherapeutics

Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics ...

Napro Biotherapeutics Incorporated

NaPro BioTherapeutics, Inc. is a natural product pharmaceutical company focused primarily on the development, manufacture and commercializa tion of paclitaxel, a naturally-occurring anti-cancer agent ...

Sephos Biotherapeutics

Sephos Biotherapeutics is a privately owned company focused on designing drugs for the treatment of cancer stem cells where the structure and biological activity of the drugs have...

Talecris Biotherapeutics Holdings Inc.

Talecris Biotherapeutics (Nasdaq: TLCR) is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders i...

Talecris Biotherapeutics, Inc.

Talecris Biotherapeutics (Nasdaq: TLCR) is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-th...

More Information about "GTC Biotherapeutics" on BioPortfolio

We have published hundreds of GTC Biotherapeutics news stories on BioPortfolio along with dozens of GTC Biotherapeutics Clinical Trials and PubMed Articles about GTC Biotherapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of GTC Biotherapeutics Companies in our database. You can also find out about relevant GTC Biotherapeutics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...


Corporate Database Quicklinks



Searches Linking to this Company Record